PT Kalbe Farma Tbk (KLBF) Q3 2026 earnings summary

Executive summary

• Unaudited 9M26 net sales reached Rp28,974,015 million, up 11.5% YoY; income attributable to owners rose 4.0% to Rp2,736,895 million.

• Net operating cash flow was Rp2,633,360 million, and cash and equivalents totaled Rp5,423,231 million at September 30, 2026.

Financial highlights

• Gross profit rose to Rp10,903,719 million from Rp10,525,524 million; cost of goods sold increased to Rp18,070,296 million from Rp15,462,772 million.

• Operating profit increased 4.6% to IDR 3,458bn, while operating margin fell to 11.9% from 12.7%.

• Income for the period was Rp2,837,405 million; basic EPS attributable to owners reached Rp60.50, versus Rp57.79 in 9M25.

• At September 30, 2026, total assets were Rp33,397,766 million, equity Rp26,580,856 million and liabilities Rp6,816,910 million.

• Other operating income included a Rp91,313 million gain on disposal of intangible assets; no adjusted earnings figure was presented.

Outlook and guidance

• Growth priorities include specialty pharmaceuticals, biologics, vaccines, cell therapy, preventive and non-curative consumer products, and nutritionals in liquid and lifestyle categories.

• Plans include expanding selected international markets, deepening strategic partnerships and developing local manufacturing through technology transfer.

• Marketing, R&D, innovation and collaboration investments are intended to support future growth and product development.